Transdermal drug delivery: 30 + years of war and still fighting!

Sandra Wiedersberg, Richard H. Guy

Research output: Contribution to journalArticlepeer-review

227 Citations (SciVal)
781 Downloads (Pure)


By any measure, transdermal drug delivery (TDD) is a successful controlled release technology. Over the last 30 + years, a steady flux of transdermal products have received regulatory approval and reached the market. For the right compounds, TDD is an effective and preferred route of administration; for others, delivery across the skin makes no sense at all. Currently, the "rules" that govern (passive) TDD feasibility are clearly understood, and research activity is focused on novel approaches that strive to subvert skin's excellent barrier function, and broaden the range of active species amenable to percutaneous administration.
Original languageEnglish
Pages (from-to)150-156
JournalJournal of Controlled Release
Early online date19 May 2014
Publication statusPublished - 28 Sept 2014


Dive into the research topics of 'Transdermal drug delivery: 30 + years of war and still fighting!'. Together they form a unique fingerprint.

Cite this